Laval, Quebec-based Klox designed LumiHeal to provide fluorescent and blue light to post-surgical incisions for scar management. The company touts it as the first fluorescent light energy (FLE)-based device cleared by the FDA.
The first-in-class, non-invasive, non-thermal platform provides treatment that utilizes FLE to reduce the appearance and feel of acute post-surgical incisions, according to a news release.
“We believe that the LumiHeal System can make a significant difference in the way we manage post-surgically incisions and opens the way to further indications for the U.S. market”, Lumiheal Therapeutics (Klox’s U.S.-based partner) CEO Howard Walthall said in the release.